Skip to main content

COVID-19

 

Clinical courses

  • New evidence COVID-19 antibodies, vaccines less effective against variants

    New research at Washington University School of Medicine in St. Louis indicates that three new, fast-spreading variants of the virus that cause COVID-19 can evade antibodies that work against the original form of the virus that sparked the pandemic. With few exceptions, whether such antibodies were produced in response to vaccination or natural infection, or were purified antibodies intended for use as drugs, the researchers found more antibody is needed to neutralize the new variants.

  • GSK and Vir Biotech COVID19 vaccine met initial pre-specified criteria in clinical trial

    Vir Biotechnology, Inc and GlaxoSmithKline plc provided an update on the VIR-7831 (GSK4182136) arm of the National Institutes of Health’s (NIH) Accelerating COVID-19 Therapeutic Interventions and Vaccines (ACTIV) Program Phase 3 clinical trial. The companies were informed that while VIR-7831 met initial pre-specified criteria to continue to the next phase of the ACTIV-3 trial and there were no reported safety signals, sensitivity analyses of the available data raised concerns about the magnitude of potential benefit.

  • Johnson and Johnson Covid-19 Vaccine receives FDA Nod for Emergency Use

    Johnson & Johnson announced that the U.S. Food and Drug Administration (FDA) has issued Emergency Use Authorization (EUA) for its single-dose COVID-19 vaccine, developed by the Janssen Pharmaceutical Companies of Johnson & Johnson, to prevent COVID-19 in individuals 18 years of age and older.

  • ‘Crowd and Mask’ Monitoring System to prevent COVID-19

    Innovators at Indian Institute of Science Education and Research (IISER), Bhopal have developed a unique ‘Crowd and Mask’ Monitoring System to prevent COVID-19 from spread. This one-of-its-kind low cost Artificial Intelligence (AI)-enabled device is portable and easy to deploy across various locations, says a statement released by the institution.

  • Job for Project Associate at IIIM | M.Pharm, MSc apply

    The Laboratory was established in 1941 as a research and production centre, known as Drug Research Laboratory of J&K State and was later taken over by Council of Scientific & Industrial Research (CSIR) of Govt. of India in December 1957 as Regional Research Laboratory, Jammu. In view of its core strength in natural products based drug discovery, the mandate of Institute was redefined in 2005 and its name changed to Indian Institute of Integrative Medicine (IIIM)

  • Moderna sends COVID-19 booster shot for NIH testing

    Moderna, Inc a biotechnology company pioneering messenger RNA (mRNA) therapeutics and vaccines, announces that it has completed manufacturing of clinical trial material for its variant-specific vaccine candidate, mRNA-1273.351, against the SARS-CoV-2 variant known as B.1.351 first identified in the Republic of South Africa, and has shipped doses to the National Institutes of Health (NIH) for a Phase 1 clinical trial that will be led and funded by the NIH’s National Institute of Allergy and Infectious Diseases (NIAID).

  • New potential drug to treat SARS-CoV-2

    A federally approved heart medication shows significant effectiveness in interfering with SARS-CoV-2 entry into the human cell host, according to a new study by a research team from Texas A&M University and The University of Texas Medical Branch (UTMB).

    The medication bepridil, which goes by the trade name Vascor, is currently approved by the U.S. Food and Drug Administration (FDA) to treat angina, a heart condition.

  • WHO COVID-19 Investigation Is Tainted by Conflict of Interest

    AIDS Healthcare Foundation (AHF) calls for the team that is currently investigating the origins of the novel coronavirus in Wuhan, China to be disbanded and reassembled by a completely independent panel with unfettered access and diplomatic immunity for all members. A conflict of interest of one of the current WHO-sanctioned team members and the tightly choreographed format of the field research cast doubt on the investigation’s credibility and the validity of the eventual findings.

  • Smiths Detection's BioFlash shown to detect airborne COVID-19

    Smiths Detection, a global leader in threat detection and security screening technologies, reports that its BioFlash® Biological Identifier is capable of detecting SARS-CoV-2 in the air following tests conducted by the United States Army Medical Research Institute of Infectious Diseases (USAMRIID).

  • Daiichi Sankyo to manufacture AstraZeneca COVID-19 vaccine in Japan

    Daiichi Sankyo Company, Limited is pleased to announce that it recently entered into an outsourcing agreement with AstraZeneca K.K. (hereinafter, AstraZeneca) to manufacture the AstraZeneca-developed COVID-19 vaccine, AZD1222, in Japan.

Subscribe to COVID-19